Pittsburgh, PA / April 30, 2014 / AntriaBio, Inc. (OTCQB: ANTB) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and CEO, Mr. Nevan Elam. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his inaugural blog post, Mr. Elam reflects on the Company's recent financing and plans to advance its lead product candidate, AB101, into clinical trials. Mr. Elam believes AB101 will have a positive impact “by lessening the therapeutic burden for individuals with diabetes.” Read the full blog post on TheChairmansBlog.com (http://www.thechairmansblog.com/antriabio/nevan-elam/introducing-antriabio/).
About AntriaBio, Inc.
AntriaBio is a biopharmaceutical company focused on developing novel therapeutic products for the diabetes market. AntriaBio's development strategy combines FDA approved pharmaceutical agents with its proprietary delivery technology. AntriaBio's lead product candidate is AB101, an injectable once-a-week basal insulin for Type 1 and Type 2 diabetes. For more information visit: www.antriabio.com.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: AntriaBio, Inc. and TheChairmansBlog.com